Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media
Type 2 (T2) inflammation plays an important role in the pathogenesis of allergic diseases such as asthma, eosinophilic chronic rhinosinusitis (ECRS), or eosinophilic otitis media (EOM). Currently, in severe asthma with the T2 phenotype, biologics targeting mediators of T2 inflammation dramatically i...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/12/4/522 |
| _version_ | 1797436788581597184 |
|---|---|
| author | Ayumi Chikumoto Keiji Oishi Kazuki Hamada Tsunahiko Hirano Tomoyuki Kakugawa Keiko Kanesada Kazuto Matsunaga |
| author_facet | Ayumi Chikumoto Keiji Oishi Kazuki Hamada Tsunahiko Hirano Tomoyuki Kakugawa Keiko Kanesada Kazuto Matsunaga |
| author_sort | Ayumi Chikumoto |
| collection | DOAJ |
| description | Type 2 (T2) inflammation plays an important role in the pathogenesis of allergic diseases such as asthma, eosinophilic chronic rhinosinusitis (ECRS), or eosinophilic otitis media (EOM). Currently, in severe asthma with the T2 phenotype, biologics targeting mediators of T2 inflammation dramatically improve the management of severe asthma. While treatment with a single biologic is common, little is known about cases of the sequential use of two biologics. Here, we report a case of severe asthma with refractory ECRS and EOM in which total control of these allergic diseases could not be achieved with a single biologic but could be achieved via the sequential use of the anti-IL-5 receptor antibody and human anti-IL-4/13 receptor monoclonal antibody. It is suggested that it is necessary to control multiple T2 inflammatory pathways to achieve total control of severe allergic diseases. Sequential biotherapy may help solve the clinical challenges associated with single-agent molecular-targeted therapies. |
| first_indexed | 2024-03-09T11:06:39Z |
| format | Article |
| id | doaj.art-f5a90a84e347451daa26c283413e58af |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-09T11:06:39Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-f5a90a84e347451daa26c283413e58af2023-12-01T00:55:46ZengMDPI AGBiomolecules2218-273X2022-03-0112452210.3390/biom12040522Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis MediaAyumi Chikumoto0Keiji Oishi1Kazuki Hamada2Tsunahiko Hirano3Tomoyuki Kakugawa4Keiko Kanesada5Kazuto Matsunaga6Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube 755-8505, JapanDepartment of Medicine and Clinical Science, Graduate School of Medicine, Yamaguchi University, Ube 755-8505, JapanDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube 755-8505, JapanDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube 755-8505, JapanDepartment of Pulmonary and Gerontology, Graduate School of Medicine, Yamaguchi University, Ube 755-8505, JapanNonohana Clinic, Yamaguchi 753-0221, JapanDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube 755-8505, JapanType 2 (T2) inflammation plays an important role in the pathogenesis of allergic diseases such as asthma, eosinophilic chronic rhinosinusitis (ECRS), or eosinophilic otitis media (EOM). Currently, in severe asthma with the T2 phenotype, biologics targeting mediators of T2 inflammation dramatically improve the management of severe asthma. While treatment with a single biologic is common, little is known about cases of the sequential use of two biologics. Here, we report a case of severe asthma with refractory ECRS and EOM in which total control of these allergic diseases could not be achieved with a single biologic but could be achieved via the sequential use of the anti-IL-5 receptor antibody and human anti-IL-4/13 receptor monoclonal antibody. It is suggested that it is necessary to control multiple T2 inflammatory pathways to achieve total control of severe allergic diseases. Sequential biotherapy may help solve the clinical challenges associated with single-agent molecular-targeted therapies.https://www.mdpi.com/2218-273X/12/4/522sequential biotherapyanti-IL-5 receptor antibodyanti-IL-4/13 receptor monoclonal antibodymultiple Type 2 inflammatory pathwayseosinophil sinusitiseosinophilia otitis media |
| spellingShingle | Ayumi Chikumoto Keiji Oishi Kazuki Hamada Tsunahiko Hirano Tomoyuki Kakugawa Keiko Kanesada Kazuto Matsunaga Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media Biomolecules sequential biotherapy anti-IL-5 receptor antibody anti-IL-4/13 receptor monoclonal antibody multiple Type 2 inflammatory pathways eosinophil sinusitis eosinophilia otitis media |
| title | Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media |
| title_full | Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media |
| title_fullStr | Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media |
| title_full_unstemmed | Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media |
| title_short | Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media |
| title_sort | sequential biotherapy targeting il 5 and il 4 13 in patients with eosinophilic asthma with sinusitis and otitis media |
| topic | sequential biotherapy anti-IL-5 receptor antibody anti-IL-4/13 receptor monoclonal antibody multiple Type 2 inflammatory pathways eosinophil sinusitis eosinophilia otitis media |
| url | https://www.mdpi.com/2218-273X/12/4/522 |
| work_keys_str_mv | AT ayumichikumoto sequentialbiotherapytargetingil5andil413inpatientswitheosinophilicasthmawithsinusitisandotitismedia AT keijioishi sequentialbiotherapytargetingil5andil413inpatientswitheosinophilicasthmawithsinusitisandotitismedia AT kazukihamada sequentialbiotherapytargetingil5andil413inpatientswitheosinophilicasthmawithsinusitisandotitismedia AT tsunahikohirano sequentialbiotherapytargetingil5andil413inpatientswitheosinophilicasthmawithsinusitisandotitismedia AT tomoyukikakugawa sequentialbiotherapytargetingil5andil413inpatientswitheosinophilicasthmawithsinusitisandotitismedia AT keikokanesada sequentialbiotherapytargetingil5andil413inpatientswitheosinophilicasthmawithsinusitisandotitismedia AT kazutomatsunaga sequentialbiotherapytargetingil5andil413inpatientswitheosinophilicasthmawithsinusitisandotitismedia |